JAK Inhibitor-Centered Therapy Improves Inflammatory Control and Cardiopulmonary Outcomes in Refractory Still's Disease with Lung Disease and Drug-Associated Immune Reaction (ACR Convergence 2026) - Sep 8, 2026 - Abstract #573; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; " We retrospectively analyzed patients with refractory Still's disease complicated by LD and DAIR who were treated with ruxolitinib or upadacitinib...(B) Mean prednisone-equivalent corticosteroid dose (mg/day) before and after JAK inhibitor therapy for all participants... Transition to JAK inhibitor-centered therapy in refractory Still's disease complicated by LD and DAIR resulted in sustained inflammatory control, meaningful reduction of glucocorticoids, and improvement of cardiopulmonary disease. These findings support therapeutic targeting of JAK-STAT signaling in this subgroup of refractory patients. Prospective evaluation with molecular endotyping and extended follow-up is warranted to define durability of response and optimize patient selection."
Cardiovascular • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
|
|
Mariana Correia Marques1; Carol Lake2; Dale Kobrin3; Emily Way4; Tova Ronis5; Michael Tsifansky6; Patrick Wood7; Isabelle Amigues8; Lana Bernstein9; Phillip Joseph10; Philip Mease11; Cory Stingl12; Erik Swenson13; Aleksander Lenert14; Ly-Lan Bergeron15; Michelle Millwood16; Estefania de Los Santos17; Joseph Rocco18; Michael Ombrello19
|